دورية أكاديمية
A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020
| العنوان: | A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020 |
|---|---|
| المؤلفون: | Aya Sugiyama, Fumie Okada, Kanon Abe, Hirohito Imada, Serge Ouoba, Bunthen E, Md Razeen Ashraf Hussain, Masayuki Ohisa, Ko Ko, Shintaro Nagashima, Tomoyuki Akita, Shinichi Yamazaki, Michiya Yokozaki, Eisaku Kishita, Junko Tanaka |
| المصدر: | Environmental Health and Preventive Medicine, Vol 27, Pp 30-30 (2022) |
| بيانات النشر: | Komiyama Printing Co. Ltd, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Public aspects of medicine |
| مصطلحات موضوعية: | sars-cov-2, antibody test, prevalence, seroconversion, general population, random sampling, japan, Public aspects of medicine, RA1-1270 |
| الوصف: | Background: This longitudinal study aimed to determine chronological changes in the seroprevalence of prior SARS-CoV-2 infection, including asymptomatic infections in Hiroshima Prefecture, Japan. Methods: A stratified random sample of 7,500 residents from five cities of Hiroshima Prefecture was selected to participate in a three-round survey from late 2020 to early 2021, before the introduction of the COVID-19 vaccine. The seroprevalence of anti–SARS-CoV-2 antibodies was calculated if at least two of four commercially available immunoassays were positive. Then, the ratio between seroprevalence and the prevalence of confirmed COVID-19 cases in Hiroshima was calculated and compared to the results from other prefectures where the Ministry of Health, Labour and Welfare conducted a survey by using the same reagents at almost the same period. Results: The numbers of participants in the first, second, and third rounds of the survey were 3025, 2396, and 2351, respectively and their anti-SARS-CoV-2 antibodies seroprevalences were 0.03% (95% confidence interval: 0.00–0.10%), 0.08% (0.00–0.20%), and 0.30% (0.08–0.52%), respectively. The ratio between the seroprevalence and the prevalence of confirmed COVID-19 cases in Hiroshima was 1.2, which was smaller than that in similar studies in other prefectures. Conclusions: The seroprevalence of anti–SARS-CoV-2 antibodies in Hiroshima increased tenfold in a half year. The difference between seroprevalence and the prevalence of confirmed COVID-19 cases in Hiroshima was smaller than that in other prefectures, suggesting that asymptomatic patients were more actively detected in Hiroshima. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1342-078X 1347-4715 |
| العلاقة: | https://www.jstage.jst.go.jp/article/ehpm/27/0/27_22-00016/_html/-char/enTest; https://doaj.org/toc/1342-078XTest; https://doaj.org/toc/1347-4715Test |
| DOI: | 10.1265/ehpm.22-00016 |
| الوصول الحر: | https://doaj.org/article/33756de4858644d1b2af6a75ddc3c057Test |
| رقم الانضمام: | edsdoj.33756de4858644d1b2af6a75ddc3c057 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 1342078X 13474715 |
|---|---|
| DOI: | 10.1265/ehpm.22-00016 |